LRMR
Larimar Therapeutics, Inc.
Set alert
2.47 USD -0.20 -7.49%
2.42 Day range 2.66
1.99 52-week range 5.95
- YTD
- -35.17%
- 1 year
- -38.86%
- Open
- 2.64
- Prev close
- 2.67
- Mkt cap
- 256.59M
- Vol
- 781.28K
- Avg vol
- 1.31M
- EPS
- -1.99
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.42
- High
- 2.66
- Forward P/E
- -2.57
- Beta
- 0.71
- Short ratio
- 5.19
- Inst. own
- 106.56%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 6.92
- 200-d avg
- 7.61
- 1y target
- 20.41
Key statistics
- Market cap
- 252.67M
- Enterprise value
- 57.52M
- Trailing P/E
- 0.00
- Forward P/E
- -2.57
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.27
- EPS (TTM)
- -1.15
- Beta
- 0.71
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -35.22M
- Total cash
- 203.71M
- Total debt
- 5.36M
- Return on equity
- -44.50%
- Shares outstanding
- 63.81M
- Short % of float
- 9.31%
- 50-day average
- 6.92
- 200-day average
- 7.61
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 20.41 +726.2% upside
Now 2.47
- Target (low)
- 12.49
- Target (mean)
- 20.41
- Target (high)
- 36.00
Ratings (0m) 11 11 buy · 0 hold · 0 sell
- Strong buy2
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.32491.
Financials — quick view
LRMR Revenue — quarterly 0
LRMR Net income — quarterly -32.78M
LRMR EPS — quarterly 0.30
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 30, 2024 | Sep 1, 2024 | -0.37 | -0.24 | +0.13 | +35.14% |
| Aug 7, 2024 | Jun 1, 2024 | -0.32 | -0.34 | -0.02 | -6.25% |
| May 9, 2024 | Mar 1, 2024 | -0.24 | -0.27 | -0.03 | -12.50% |
| Mar 14, 2024 | Dec 1, 2023 | -0.25 | -0.30 | -0.05 | -20.00% |
| Nov 14, 2023 | Sep 1, 2023 | -0.23 | -0.21 | +0.02 | +8.70% |
| Aug 10, 2023 | Jun 1, 2023 | -0.21 | -0.19 | +0.02 | +9.52% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 16, 2024 | Oppenheimer | init | — | Outperform |
| Oct 3, 2024 | Wedbush | init | — | Outperform |
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- larimartx.com
News
- 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
- Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Larimar Therapeutics Appoints John Harlow As President and COO, Effective September 29
- Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
- 5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
- BlackRock Inc. Buys New Position in Larimar Therapeutics, Inc. $LRMR
- Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Brokerages
- Dimensional Fund Advisors LP Purchases 470,968 Shares of Larimar Therapeutics, Inc. $LRMR
- Wedbush Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $11
- Larimar Therapeutics Q2 EPS $(0.30) Beats $(0.39) Estimate
Your note
Sign in to keep a note on LRMR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEN MAIMON CAROLE S | Chief Executive Officer | Stock Award(Grant) | Jan 16, 2024 | 332,954 |
| CELANO MICHAEL | Chief Financial Officer | Stock Award(Grant) | Jan 16, 2024 | 143,996 |
| CLAYTON RUSSELL | Officer | Stock Award(Grant) | Jan 16, 2024 | 22,500 |
| FLYNN JAMES E | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 15, 2024 | 0 |
| HAMILTON THOMAS EDWARD | Director | Purchase | Feb 15, 2024 | 724,231 |
| SHANKAR GOPI | Officer | Stock Award(Grant) | Jan 16, 2024 | 27,500 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 33.28% | 21,231,974 | 84.08M | Sep 29, 2024 |
| RA Capital Management, L.P. | 9.47% | 6,045,351 | 23.94M | Sep 29, 2024 |
| Janus Henderson Group PLC | 8.72% | 5,566,855 | 22.04M | Sep 29, 2024 |
| Goldman Sachs Group Inc | 6.66% | 4,249,491 | 16.83M | Sep 29, 2024 |
| Blue Owl Capital Holdings LP | 6.53% | 4,166,829 | 16.50M | Sep 29, 2024 |
| Blackrock Inc. | 4.66% | 2,972,953 | 11.77M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.10% | 1,341,890 | 5.31M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.72% | 1,095,985 | 4.34M | Oct 30, 2024 |
| Fidelity Advisor Biotechnology Fund | 0.82% | 524,800 | 2.08M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.80% | 510,244 | 2.02M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.68% | 431,074 | 1.71M | Aug 30, 2024 |
| Alger Fund-Small Cap Growth Fund | 0.63% | 398,960 | 1.58M | Jul 30, 2024 |